Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to ...

In 2008, three years after Natalie Hayden was diagnosed with Crohn’s disease, she was hospitalized with an abscess the size of a tennis ball in her small intestine. Until then, Hayden had been ...

The US Food and Drug Administration (FDA) has approved the biologics license application for a subcutaneous formulation of lecanemab (Leqembi Iqlik) for weekly maintenance dosing to treat Alzheimer’s ...

Single-use and reusable needle-free injection devices will be designed for precise self-administration and home use. PharmaJet injector pens are intended for needle-free subcutaneous delivery of a ...

BURLINGTON, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to ...

The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...

Recommendation based on TULIP-SC Phase III trial results showing first-in-class Saphnelo reduced disease activity via once-weekly subcutaneous administration AstraZeneca's Saphnelo (anifrolumab) has ...

CHMP backs once-weekly subcutaneous option for systemic lupus erythematosus AstraZeneca’s Saphnelo (anifrolumab) has received a positive recommendation from the Committee for Medicinal Products for ...

If approved, patients could self-administer a weekly dose at home as an alternative to hospital intravenous dosing.